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Abstract
Background: A 3-yr study examined whether prepartum treatment with casein hydrolyzate in combination with
antibiotic, as routinely used in Israel for dry cow therapy, improved bacterial cure and increased milk yield in
subsequent lactations in comparison with treatment with antibiotic alone. The vast majority of bacterial isolates in
samples collected prior to drying-off comprised coagulase-negative staphylococci, mostly as Staph. chromogenes.
Results: Bacterial cure associated with the combined treatment was 73.8% in cows, significantly higher than the
51.7% cure recorded when cows were treated only with antibiotic. During the study, the annual milk yield of non-
casein hydrolyzate treated and treated control cows increased at ~2% per year, which is consistent with the
national annual increase attributed to genetic selection. In cows treated with casein hydrolyzate the increase was
9% (above the 2% expected) in the first lactation after the treatment, and 6.3% (above the 4% expected for
2 years) in the second lactation after treatment. These increases were significantly higher than those in the controls
and those expected through genetic improvement.
Conclusions: Treatment with casein hydrolyzate at dry-off was shown to be a viable mean to eliminate existing
environmental bacterial infection, and to improve milk yield in the next lactation.
Background
Active involution of the mammary gland is induced by
milk stasis, which in turn triggers a negative feedback reg-
ulatory mechanism that leads to precipitous dry off of
milk secretion and shrinkage of the secretory tissue (par-
enchyma) of the mammary gland [1,2]. Involution in cows
[3-6] and mice [7,8] is associated with an inflammatory
response that is characterized by activation of the glandu-
lar immune system, accelerated apoptosis of epithelial
cells, and tissue remodeling [1,2,9]. The process of active
involution that follows milk stasis in goats [10] and cows
[11] can be triggered by the induction of intensive plasmin
activity in milk; this, in turn liberates casein-derived active
peptides [12]. Infusion of casein hydrolyzate (CNH), which
contains active casein-derived peptides, dramatically accel-
erated the involution, which was completed within 3 days
in goats and cows, compared with 3-4 weeks without such
treatment, and resulted in a marked reduction in milk
yield (MY) even after the first day of treatment [10,11,13].
These responses were manifested in the mammary secre-
tion within 8 h after the first application, which relates to
the forceful activation of the innate immune system and
the drastic reduction in nutrient availability (mainly lac-
tose) for bacterial growth [13].
These properties of CNH were exploited successfully
to eliminate quarter-udder infection by drying-off the
infected glands during lactation, which resumed normal
milk secretion in the subsequent lactation [14]. More-
over, it was found that infusion of CNH induced marked
bactericidal and bacteriostatic responses against udder
pathogens, such as Escherichia coli and Staphylococcus
aureus, in the involuted gland secretion as tested
in vitro [13].
Casein hydrolyzate may be used as a tool to reduce
the discomfort associated with drying-off of modern
high-yielding dairy cows, by preventing the enormous
udder engorgement that typically develops with this
management process [15].
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It has been well established that the beginning of the
dry period in dairy cows is associated with an increased
risk of acquiring intramammary infection (IMI)[16].
This increased risk is closely related to MY at drying-
off, and may be related to increased incidence of milk
leakage from the udder [17] and the slow activation of
the innate immune system [13]. Each 5 kg/d increase in
MY above 12.5 kg/d at dry-off increase the probability
of acquiring new IMI with environmental bacteria by
77% [17]. Thus, in Israel and in other countries, most
cows are at high risk of acquiring IMI at drying-off,
because they are still producing milk at over 20 L/d.
It was hypothesized that acceleration of the involution
process might increase bacterial cure [18-20] and result
in increased MY in the subsequent lactation [1]. The
aims of the present study were to determine whether
intramammary CNH treatment at drying-off would
result in improved bacterial cure of existing IMI, and
increased MY in the subsequent lactation. Since it was
the first time that the efficacy of CNH as dry cow treat-
ment (DCT) was tested and because the study was per-
formed in a commercial herd, a combination of CNH
with an antibiotic treatment was used instead of CNH
alone. Due to management limitations, CNH was tested
only during one year of the 3-year study. For testing the
efficiency of the CNH treatment for curing/preventing
bacterial infection the year prior to the CNH usage and
the year after served as control. To overcome the effects
associated with genetic improvement, the MY of heifers,
which entered the herd throughout the 3-year study was
analyzed and served as a covariate.
Methods
Materials
A commercial nafcillin/procaine penicillin G/dihydros-
treptomycin preparation, Nafpenzal DC (Intervet, the
Netherlands), which is a medication for DCT, was used
according to the manufacturer's instructions. A pre-com-
mercial prototype of the CNH was prepared under Good
Laboratory Practice conditions [15] and was used in
combination with Nafpenzal DC for DCT. The CNH
solution was a sterile pyrogen-free liquid preparation that
was stored in sterile vials [15]. Each infusion into a quar-
ter contained 10 mL of CNH, with a peptide concentra-
tion of 7.2 mg/mL followed by a Nafpenzal DC tube.
Study design
All protocols were approved by the Institutional Animal
Care Committee of the Agricultural Research Organiza-
tion, which is the legitimate body for such authoriza-
tions in Israel.
The study extended over 3 years and is summarized in
Table 1; it covered Israeli Holstein cows (pluriparous;
second lactation and above) and heifers (first lactation)
of the commercial-experimental herd of the Agricultural
Research Organization, Bet Dagan, Israel, which holds
250 animals. Cows and heifers were held in high-roof
barns suitable for sub-tropical conditions, and were fed
a typical Israeli TMR comprising 65% concentrates and
17% protein. The food and water managers were located
in the shed. During the summer months (June to
September) the cows are routinely cooled by fans and
sprinklers. Two dry-off treatments were compared: Naf-
penzal DC, and Nafpenzal DC combined with CNH
infused to each quarter in the treated cows. The cows
were treated in accordance with their dry-off schedules.
Cows included in "Period 1" (August 2004 to August
2005) were dry-off treated with antibiotic. In the follow-
ing season, from September 2005 to June 2006 (Period
2), the vast majority of the cows in the herd were dry-
off treated with a combination of antibiotic and CNH,
and a group of 17 cows, that served as control cows,
were treated only with antibiotic for DCT. In the third
season of observation, from July 2006 to April 2007
(Period 3), all the cows were dry-off treated with anti-
biotic. All the heifers that joined the herd during Peri-
ods 1 to 3 were included to enable comparison of the
evolution of their MY with that of the experimental
cows. Heifers were not treated for DCT. The number of
animals recorded in each season is indicated in Table 1.
Because of the natural dynamics of the herd population,
41 cows were observed during all 3 Periods, 101 cows in
2 Periods and 162 cows in one Period; a total of 481
cows (Table 1).
Table 1 Experimental structure: animals (number and types), treatments, and Periods
Period Time Animals Number Treatment
1 Aug. 04 - Aug. 05 heifers 74 None
cows 111 Naf. DC
2 Sep. 05 - June 06 heifers 56 None
cows 92 Naf. DC + CNH
control cows 17 Naf. DC
3 July 06 - April 07 heifers 48 None
cows 83 Naf. DC
Naf. - Nafpenzal.
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The average MY in this farm at 2005 was 11,135 L
during 305 days of lactation and the average bulk tank
somatic cell count (SCC) was 236,000. Milk yield and
SCC were retrieved from the routine monthly record of
this information for each Holstein cow in Israel by the
Israeli Cattle Breeders' Association. All animals were
sampled by quarter, for SCC and bacterial udder infec-
tion, as follows: 3 times at weekly intervals during the
last month before drying-off; at the time of parturition
(days 0 to 3); and monthly for up to 100 (range 95 to
105) days during the subsequent lactation. Thus, each
cow was sampled 4 times during this period. A cow was
considered infected when at least two of the milk sam-
ples were positive with the same bacterium accompa-
nied by increased SCC.
Bacteriological analysis
Duplicate quarter foremilk samples were taken asepti-
cally and submitted to the laboratory within one h. Bac-
teriological analysis was performed according to
accepted standards of microbiological procedures as
described by the National Mastitis Council [21]. All
samples were taken during milking. Udder quarters
were cleaned and disinfected prior to sampling with a
non-woven disposable commercial wipe that was mois-
tened with chlorhexidine, cetrimide and ethanol. The
three first squirts of milk were discarded and approxi-
mately 3-5 ml of milk were taken in sterile tubes. From
every milk sample, 0.01 mL was spread onto blood-agar
plates (Bacto-Agar; Difco Laboratory Becton, Dickinson
and Company, France) containing 5% of washed red
sheep blood cells and on MacConkey plates. All plates
were incubated at 37°C and examined for growth after
18 and 42 h. If there was no agreement between dupli-
cates the quarters were sampled again. Colonies sus-
pected to be staphylococci were tested for coagulase
(tube test, Anilab, Rehovot, Israel). Species identification
was carried out with the API STAPH-IDENT, 32 Staph
kit or rapid ID 32 STREP (bioMerieux S.A., 69280
Marcy l'Etoile, France). When micrococci-like bacteria
in given sample matched the reference kit specie by >
90%, the specie was regarded as specific.
Bacterial cure was defined as the absence of the bac-
teria identified in the same quarter in the month pre-
ceding drying-off from the milk sampled during the first
100 days of a new lactation (i.e., in at least 4 postpartum
milk sampling). New infection was defined as the
appearance of infection that was absent from samples
taken before drying-off in the previous lactation in a
given quarter at the start of the new lactation. In order
to be defined as new infection, the infection could be
identified in milk sampled during the first 3 d postpar-
tum, or in the first month of postpartum samples;, it
should have persisted for at least 2 additional samplings,
i.e., during the first 100 days of lactation. Clinical infec-
tions were defined by the herd veterinarian by for-
stripping milk of suspicious cows. The SCC in milk was
determined in the central laboratory of the Israeli Dairy
Cow Breeders' Association, according to established
standard procedures [22].
Statistical Analysis
All the statistical analysis procedures were carried out
with the JMP software [23]. All the main measures (cure
rate, CC and milk yield) were analyzed according to the
following model:
Y eijk i j ij l il ijkl= + + + + + +μ α β αβ αΚ Κ
where μ = Mean of all data, αi = effect of Period, i (i =
1, 2 or 3); βj = effect of cow category (j = 1, 2 or 3 for
heifer, experimental, and control cow, respectively); αβij
= the cow category × Period interaction; Κl = effect of
lactation number of cows (l = 2, 3, or > 4); αΚil - inter-
action of period and cows lactation number and eijkl =
residual variance between measurements (random
error).
Because the effects of Κl and αΚil were not significant,
similar statistical results were obtained when treatments
were also analyzed by the Pearson's chi-square (χ2) test:
Nafpenzal DC and Nafpenzal DC combined with CNH
were compared by the χ2 testfor their effects on: quar-
ter's bacterial cure and acquisition of new infections in
experimental cows from Periods 2 and 3. For simplicity,
only the χ2 analysis was presented in Table 2.
Milk yield comparisons were based on the monthly
MY during the first 5 months of lactation according to
the above model.
The above statistical model with the inclusion of the
effect of SCC (categories of < 50,000; 50,000 to 700,000;
and > 700,000) and the interaction of SCC with period
effect was used to analyze the effect of SCC on milk
yield. Alternatively, for all three periods, the effect of the
same SCC categories on milk yield was analyzed by the
χ2 test. The statistical analysis by both methods, yielded
similar predictions, and for simplicity the χ2 test results
are presented in Table 3.
Results
Bacteriology
Of the 92 cows (368 glands) that gave birth during Per-
iod 2 and had been treated with Nafpenzal DC in com-
bination with CNH in the dry period at the end of
Period 1, 88.6% of the glands (326/368) were uninfected,
and infection was detected in 11.4% (42/368) at dry-off
(Table 2). Of the 326 uninfected glands, 312 (95.7%)
remained uninfected through 100 d of the lactation
(range 95 to 105 d), and 14 (4.3%) exhibited new
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bacterial infection immediately postpartum (day 0 to 3),
and this persisted in sub-clinical forms through 100 d of
the lactation. In 28 (8.6%) out of 326 glands newly
acquired bacterial clinical infection was detected during
the first month. Bacterial cure of cows entering the dry
period infected was detected in 31 out of 42 glands
(73.8%), and 11 out of 42 (26.2%) glands remained
infected with the same bacteria (Table 2).
For comparison among the 83 cows (332 quarters) that
gave birth during Period 3 and had been treated with
Nafpenzal DC during the preceding dry period, 82.5% of
the glands were bacteria free and 17.5% were infected at
dry-off (Table 2). Of the 274 uninfected glands, 259, i.e.,
94.5%, remained uninfected through 100 d of the lacta-
tion, and 15, i.e., 5.5%, exhibited new bacterial infection
immediately postpartum (days 0 to 3), and this infection
persisted sub-clinically through 100 d of the lactation. In
20 (7.3%) of the 274 glands, newly acquired clinical bac-
terial infection was detected during the first month of
lactation (Table 2). Bacterial cure of cows that entered
the dry period infected was observed in 30 out of the 58
glands (51.7%), and 28 (48.3%) glands remained infected
with the same bacteria (Table 2).
The vast majority of bacterial isolates (92%) in the
month preceding the dry period were identified as
coagulase negative staphylococci (CNS), mostly Staph.
chromogenes (85%). Thus, 'bacterial cure' by DCT in the
present study refers almost exclusively to cure from
CNS infection. New infections that were identified on
day 0 were not associated with clinical mastitis and
were caused exclusively by CNS (7%); these infections
developed into chronic infections that persisted for at
least 100 d. The vast majority (93%) of bacterial infec-
tions detected during the first month caused clinical
mastitis; E. coli and Streptococcus dysgalactiae were
identified as the causative agents. Based on their absence
in the next samplings, it can be concluded that these
infections were cured either spontaneously (mostly
E. coli) or by treatment with antibiotic. In few cases
(1 to 2 per lactation), the infection did not cured and
was a ground for culling. Thus, routine antibiotic treat-
ment with Nafpenzal DC at dry-off provided only 51.7%
cure whereas this treatment in combination with CNH
significantly increased the cure to 73.8% (Table 2P =
0.025). No differences were found between the treat-
ments in new infection rates, either with CNS during
the dry period or with E. coli and Streptococcus dysga-
lactiae during the lactation.
Somatic Cells
The proportion of udders with SCC less than 50,000
cells/mL increased from 54.9% in Period 1 to 65.7% in
Period 2 and to 66.3% in Period 3, whereas the propor-
tions with SCC in the range of 50,000 to 700,000 were
24.4, 15.8, and 15.7% in Periods 1, 2, and 3, respectively.
Although the proportion of cows with lower SCC
increased in Periods 2 and 3, the differences were not
significant (Table 3). The numerical changes in the rates
of SCC > 700,000 and of clinical infections in the 3 Peri-
ods were not significant.
Table 2 Bacterial status (infected, noninfected, subclinical, clinical and cured) in Period 2 (experimental, following
Nafpenzal DC + CNH at DCT) and Period 3 (control, following Nafpenzal DC)
Period 2 (experimental period) Period 3 (control period) P [χ2]
Before drying-off Cow/glands 92/368 83/332 NS
Uninfected 326/368 (88.6) 274/332 (82.5) NS
Infected 42/368 (11.4) 58/332 (17.5) NS
Postpartum Uninfected1 312/326 (95.7) 259/274 (94.5) NS
Subclinical2 14/326 (4.3) 15/274 (5.5) NS
Clinical3 28/326 (8.6) 20/274 (7.3) NS
Cured4 31/42 (73.8) 30/58 (51.7) 0.025
Not Cured 5 11/42 (26.2) 28/58 (48.3) 0.025
1 Uninfected quarter before drying-off and uninfected at parturition.
2 New Infection, subclinical - Infection was detected during parturition and in the first 100 days in the new lactation: The same udders were uninfected before
drying-off.
3 New Infection, clinical - Infection was detected during the first month after parturition and remained for the first 100 days in the new lactation: The same
udders were uninfected before drying-off.
4Cure - Bacteria detected in the month preceding dry-off was not detected in the same udder during the first 100 days of lactation.
5 Not Cured - The reciprocal of cured: Bacteria detected in given udders in the month preceding dry-off was also detected in the same udder during the first
100 days of the subsequent lactation.
Table 3 Distribution of SCC (cells/ml) in Periods 1, 2
and 3
SCC (category) Period P[χ2]
1 2 3
< 50,000 54.9 65.7 66.3 NS
50 - 700,000 24.4 15.8 15.7 NS
> 700,000 9.9 9.2 10.1 NS
Clinical infection 10.8 9.3 7.8 NS
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Milk Yield
The MY of the heifers increased by 2% (about 220 L per
cow) each year, from 5,130 L over 5 months in Period 1
to 5,323 L over 5 months in Period 3 (Figure 1). A simi-
lar increase of about 2% from Period 1 to Period 2
(6,374 to 6,526 L over 5 months) was recorded in the 17
control cows. The increase in MY among the heifers
and the pluriparous control cows was not significant. In
contrast, a significant (P < 0.0001) increase in MY from
Period 1 to Period 2 by about 760 L per cow (i.e., from
6,374 in the first 5 month of period 1 to 7,132 L per
cow in the first 5 month of period 2 following CNH
treatment at dry-off of period 1) over 5 months was
recorded in the pluriparous cows. Thus, the yield
increase of the tested cows was 9.9% higher than the
expected 2% per year (P < 0.001). These significant dif-
ference (P < 0.0001) were maintained in Period 3, in
which the increase in MY was 10.4% higher than in Per-
iod 1 (from 6,374 in the first 5 month of period 1 to
7,033 L in the first 5 month of period 3 following CNH
treatment at dry-off of period 1), (6.3% higher the 4%
expected; P < 0.001). These differences remained highly
significant, even after accounting for the natural annual
2% increase in MY in the whole herd, as recorded in the
control groups of heifers and cows (Figure 1).
Analysis of the effect of SCC on MY (Table 3), indi-
cates that the non-significant reduction in SCC level in
the experimental cows cannot explain the increase in
MY in those cows.
Discussion
Study Design
The present study was a feasibility study intended to ana-
lyze the effect of CNH treatment in a commercial herd
with minimal interference to its day-to-day routine, which
explains the somewhat unusual experimental design. The
potential pitfalls in such a design are that it is subjected to
confounding results because of year-to-year variations of
food composition, environmental conditions, management
etc. Thus, a special precautions in the experimental design
included the use of heifers as control for changes relating
to genetic improvement of MY, to account for such inter-
ferences, and therefore the results reflect the studied
effects of the CNH dry-off treatment.
CNH Treatment Improved Bacterial Cure of CNS
The present results show that treatment with antibiotic
plus CNH DCT was effective in curing CNS IMI. This
is important because: (i) it provides a means for pre-
venting deterioration in milk quality and associated eco-
nomic losses; and (ii) it provides a potential means to
prevent the hazard associated with routine use of high
doses of antibiotic, with blanket DCT procedures, that





























































Figure 1 Milk yield during first 5 months of lactation (kg).
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and other countries. Although in the present study,
treatment with CNH was accompany by antibiotics, the
significant improvement in bacterial cure in comparison
to treatment with antibiotic alone under farming condi-
tions provided evidence that intra-mammary CNH treat-
ment has the potential for being developed into an
effective non-antibiotic, non-hormonal DCT for bacter-
ial cure. Nevertheless, in order to advance this potential,
the benefit in using CNH over conventional antibiotic
DCT should be demonstrated in a controlled study at
dry-off.
A decade ago, CNS were often regarded as pathogens
of minor importance [24,25], especially in comparison
with Staph. aureus, streptococci, and coliforms, which
may cause severe mastitis. Nevertheless, in many coun-
tries, including Israel, CNS are the predominant patho-
gens associated with mastitis [24-27]. Mastitis caused by
CNS usually remains subclinical or mildly clinical
[28,29], but it may decrease milk production [22,30].
Leitner et al. [22,31,32] have shown that losses in curd
yield caused by the use of CNS-infected milk are several
times as great as the milk losses, because of simulta-
neous deterioration in milk quality. Thus, if milk is
being allocated for cheese production, the economic
burden imposed on dairies by loss in curd yield is
greater than that imposed on farmers by loss of MY
[22].
Although we cannot exclude the possibility of reinfec-
tion with the same species following its elimination, we
assume that in the present study the CNS infections
recorded immediately postpartum persisted in the udder
through the entire lactation. This conclusion is consis-
tent with evidence that CNS are capable of persisting in
the udder for months or even throughout the lactation
[28,29,33].
Some studies have found rather high spontaneous
CNS cure rates of about 60 to 70% during the dry per-
iod [34], whereas others found markedly lower rates,
ranging from 15.5 to 44% [16,35]. In a broad survey of
heifers in the USA and Canada it was found that quar-
ters that were infected prepartum, mostly with CNS,
and were treated with antibiotics had a 59.5% cure rate,
compared with a spontaneous cure rate of 31.7% [36]. A
study on heifers in 2 research dairy herds yielded a very
similar CNS cure rate [37]. The somewhat lower cure
rate obtained with antibiotic DCT in the present study
may be related to the fact that our subjects were cows,
or to the stricter criteria we applied to define a cure,
compared with that used in standard definitions, i.e.,
absence of infection during the first month of lactation.
Burriel [38] found that CNS can adhere to and produce
slime in various tissues, including epithelial cells of the
mammary gland. Thus, the absence of CNS from a cul-
ture of a given sample does not necessary indicate their
absence from the sampled tissue [39]. This hypothesis is
supported by the findings of a large study in Norway
that covered a total of 684 cows from 288 different
herds in 3 Norwegian regions, DCT of infected quarters
led to a 5.2:1 greater probability of the quarters being
healthy within 30 ± 17 days into the next lactation than
that in control (non-treated) groups. Nevertheless, the
overall frequency of CNS in the sampled quarters of
cured cows at the end of lactation was no different from
that among of the control cows [40]. The above findings
justify our more strict criteria for defining a cure, and
also emphasize that the success of the present CNH
treatment in significantly improving the CNS cure rate
was genuine.
In the present study none of the cows were infected
with Staph. aureus, and the numbers of cows infected
with coliforms and streptococci were too low to assess
the efficacy of the CNH treatment in curing or prevent-
ing such infections. However, in a previous study, CNH
treatment of single quarters during lactation has been
shown to be effective in curing chronic and subclinical
mastitis associated with these bacteria [14]. Thus, it is
worth further investigating the potential benefit of
applying this method as a DCT to cure and reduce the
SCC counts in herds having higher than the typical pro-
portion of coliforms, streptococci and Staph. aureus IMI
at dry-off in Israel.
DCT with CNH Increased Milk Yield
The progressive increase in MY at 2% per year in heifers
or in the control cows is typical of the yearly improve-
ment in MY attributed to genetic improvement in Israeli
dairy herds [41]. Thus, the increase in MY that was
recorded in the experimental cows considerably
exceeded any plausible trend. No such response was
recorded in cows treated with antibiotic only, i.e., the 17
control cows and those observed in Period 2 that had
joined the trial as heifers in Period 1 and 2, therefore
this MY enhancement can be related exclusively to the
effect of treating the cows with CNH.
Two hypotheses may account for this increase. First, it
may relate to the higher cure rate and the reduction in
the population of SCC that typically is negatively related
to MY [20]. However, analysis of MY as related to SCC
distribution indicates that in the present case the effect
of CNH treatment on lowering of SCC was far from sig-
nificant, probably because the infection rate and, there-
fore, the SCC, were initially low and also because
treatment did not affect new IMI in the subsequent lac-
tation. Thus, in herds with poorer initial conditions, this
effect would be expected to be more noticeable. The
second hypothesis relates to the fact that treatment with
CNH accelerated gland involution [11,13]. Thus, this
procedure probably increased epithelial cell apoptosis at
Leitner et al. BMC Veterinary Research 2011, 7:3
http://www.biomedcentral.com/1746-6148/7/3
Page 6 of 8
the start of the dry period. As the gland parenchyma
rebuilt itself during the period preceding the subsequent
parturition, it may be expected that it would be com-
posed of larger proportion of newly synthesized epithe-
lial cells, which would be expected to enhance the gland
milk production capacity [1]. Our results suggest that
this effect persisted through two subsequent lactations.
Conclusion
This study provided evidence that intra-mammary CNH
treatment has the potential for development as an effec-
tive non-antibiotic, non-hormonal DCT for bacterial
cure and for enhanced MY in the subsequent lactation.
Further research along this line is therefore warranted,
particularly under the following conditions: (i) In herds
presenting broader bacterial infection status and higher
bulk tank SCC; (iii) In combination with teat sealers,
thus contributing also to prevention of new IMI around
parturition (iv) In exploiting the accelerating effect of
CNH treatment on the involution rate, to shorten the
dry period without impairing the next-lactation MY, or
even improving it and (v) Because it is a natural pro-
duct, CNH treatment has the potential to prevent the
transmission of methicillin resistant genes and those
resistant to other antibiotics.
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